321 related articles for article (PubMed ID: 27841037)
1. Targeting reactive oxygen species in development and progression of pancreatic cancer.
Durand N; Storz P
Expert Rev Anticancer Ther; 2017 Jan; 17(1):19-31. PubMed ID: 27841037
[TBL] [Abstract][Full Text] [Related]
2. KRas, ROS and the initiation of pancreatic cancer.
Storz P
Small GTPases; 2017 Jan; 8(1):38-42. PubMed ID: 27215184
[TBL] [Abstract][Full Text] [Related]
3. Measurement of Reactive Oxygen Species by Fluorescent Probes in Pancreatic Cancer Cells.
Luo Y; Wang D; Abbruzzese JL; Lu W
Methods Mol Biol; 2019; 1882():207-219. PubMed ID: 30378057
[TBL] [Abstract][Full Text] [Related]
4. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanism of intraductal papillary mucinous neoplasm and intraductal papillary mucinous neoplasm-derived pancreatic ductal adenocarcinoma.
Fukuda A
J Hepatobiliary Pancreat Sci; 2015 Jul; 22(7):519-23. PubMed ID: 25900667
[TBL] [Abstract][Full Text] [Related]
6. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
[TBL] [Abstract][Full Text] [Related]
7. Constitutively active Akt1 cooperates with KRas(G12D) to accelerate in vivo pancreatic tumor onset and progression.
Albury TM; Pandey V; Gitto SB; Dominguez L; Spinel LP; Talarchek J; Klein-Szanto AJ; Testa JR; Altomare DA
Neoplasia; 2015 Feb; 17(2):175-82. PubMed ID: 25748236
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.
Stellas D; Szabolcs M; Koul S; Li Z; Polyzos A; Anagnostopoulos C; Cournia Z; Tamvakopoulos C; Klinakis A; Efstratiadis A
J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25306215
[TBL] [Abstract][Full Text] [Related]
9. Critical role of oncogenic KRAS in pancreatic cancer (Review).
Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
[TBL] [Abstract][Full Text] [Related]
10. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
11. Intratumor Heterogeneity of KRAS Mutation Status in Pancreatic Ductal Adenocarcinoma Is Associated With Smaller Lesions.
Nagawkar SS; Abu-Funni S; Simon E; Bick T; Prinz E; Sabo E; Ben-Izhak O; Hershkovitz D
Pancreas; 2016 Jul; 45(6):876-81. PubMed ID: 26646269
[TBL] [Abstract][Full Text] [Related]
12. E-cadherin expression in obesity-associated, Kras-initiated pancreatic ductal adenocarcinoma in mice.
Stark AP; Chang HH; Jung X; Moro A; Hertzer K; Xu M; Schmidt A; Hines OJ; Eibl G
Surgery; 2015 Dec; 158(6):1564-72. PubMed ID: 26297056
[TBL] [Abstract][Full Text] [Related]
13. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
[TBL] [Abstract][Full Text] [Related]
14. RET, a targetable driver of pancreatic adenocarcinoma.
Amit M; Na'ara S; Fridman E; Vladovski E; Wasserman T; Milman N; Gil Z
Int J Cancer; 2019 Jun; 144(12):3014-3022. PubMed ID: 30515799
[TBL] [Abstract][Full Text] [Related]
15.
Shiroma N; Arihiro K; Oda M; Orita M
J Clin Pathol; 2018 Oct; 71(10):865-873. PubMed ID: 29695486
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic KRas-induced Increase in Fluid-phase Endocytosis is Dependent on N-WASP and is Required for the Formation of Pancreatic Preneoplastic Lesions.
Lubeseder-Martellato C; Alexandrow K; Hidalgo-Sastre A; Heid I; Boos SL; Briel T; Schmid RM; Siveke JT
EBioMedicine; 2017 Feb; 15():90-99. PubMed ID: 28057438
[TBL] [Abstract][Full Text] [Related]
17. The conditional expression of KRAS G12D in mouse pancreas induces disorganization of endocrine islets prior the onset of ductal pre-cancerous lesions.
Gout J; Pommier RM; Vincent DF; Ripoche D; Goddard-Léon S; Colombe A; Treilleux I; Valcourt U; Tomasini R; Dufresne M; Bertolino P; Bartholin L
Pancreatology; 2013; 13(3):191-5. PubMed ID: 23719586
[TBL] [Abstract][Full Text] [Related]
18. ATDC induces an invasive switch in KRAS-induced pancreatic tumorigenesis.
Wang L; Yang H; Abel EV; Ney GM; Palmbos PL; Bednar F; Zhang Y; Leflein J; Waghray M; Owens S; Wilkinson JE; Prasad J; Ljungman M; Rhim AD; Pasca di Magliano M; Simeone DM
Genes Dev; 2015 Jan; 29(2):171-83. PubMed ID: 25593307
[TBL] [Abstract][Full Text] [Related]
19. Characterization of KRAS Mutation in Acinar and Langerhans Islet Cells of Patients With Pancreatic Ductal Adenocarcinoma.
Wang Z; Zhang C; Nagee K; Mohammadi A; Monteiro C
Pancreas; 2016 Mar; 45(3):337-41. PubMed ID: 26474433
[TBL] [Abstract][Full Text] [Related]
20. CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer.
Purohit A; Varney M; Rachagani S; Ouellette MM; Batra SK; Singh RK
Oncotarget; 2016 Feb; 7(6):7280-96. PubMed ID: 26771140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
